3:58 PM
Sep 21, 2012
 |  BC Extra  |  Company News

Eylea gets expanded label, CHMP recommendation

FDA approved an sBLA from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to expand the label for Eylea aflibercept to include treatment of macular edema following central retinal...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >